Targeted deletion of Vegfa in adult mice induces vision loss

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 4213-4217

  Kurihara, Toshihide ^a   Westenskow, Peter D ^a   Bravo, Stephen ^a   Aguilar, Edith ^a   Friedlander, Martin ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPSIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOROID CAPILLARY LAYER; COLOR VISION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ELECTRORETINOGRAPHY; GENE DELETION; GENE INACTIVATION; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RETINA MACULA VITELLIFORM DEGENERATION; RETINA NEOVASCULARIZATION; VASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANIMALS; BLINDNESS; EYE PROTEINS; GENE DELETION; MICE; MICE, TRANSGENIC; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868613782     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65157     Document Type: Article

References (34)

1. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci. 2002;43(11):3500-3510. (Pubitemid 35334359)
2. Gerhardt H, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177. (Pubitemid 36870177)
3. Le YZ, Bai Y, Zhu M, Zheng L. Temporal requirement of RPE-derived VEGF in the development of choroidal vasculature. J Neurochem. 2010; 112(6):1584-1592.
4. Marneros AG, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167(5):1451-1459. (Pubitemid 41541430)
5. Krzystolik MG, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346. (Pubitemid 34250056)
6. Aiello LP, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995; 92(23):10457-10461.
7. Cvetanovic M, Patel JM, Marti HH, Kini AR, Opal P. Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med. 2011;17(11):1445-1447.
8. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A. 2002;99(18):11946-11950. (Pubitemid 34994504)
9. Robinson GS, et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 2001;15(7):1215-1217.
10. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816. (Pubitemid 40051904)
11. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
12. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. (Pubitemid 44511557)
13. Le YZ, et al. Inducible expression of cre recombinase in the retinal pigmented epithelium. Invest Ophthalmol Vis Sci. 2008;49(3):1248-1253.
14. Ames A. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J Neurosci. 1992;12(3):840-853.
15. Johnson JE, et al. Spatiotemporal regulation of ATP and Ca2+ dynamics in vertebrate rod and cone ribbon synapses. Mol Vis. 2007;13:887-919.
16. Saint-Geniez M, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One. 2008;3(11):e3554.
17. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPEderived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009; 106(44):18751-18756.
18. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2002; 43(6):1986-1993. (Pubitemid 34587051)
19. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010;120(9):3033-3041.
20. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474-1485.
21. Forsythe JA, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613. (Pubitemid 26272112)
22. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med. 2011;365(6):537-547.
23. Arany Z, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451(7181):1008-1012. (Pubitemid 351301733)
24. Schmidt D, et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. Embo J. 2007;26(3):710-719.
25. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118(3):523-530.
26. Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358(11):1129-1136. (Pubitemid 351398487)
27. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490-501.
28. Papadopoulos N, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;2012(2):3.
29. Gerber HP, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999; 126(6):1149-1159.
30. Ryan HE, et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 2000;60(15):4010-4015. (Pubitemid 30636574)
31. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif- 2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301-2306. (Pubitemid 46391392)
32. Dorrell MI, et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest. 2009;119(3):611-623.
33. Kurihara T, Westenskow PD, Krohne TU, Aguilar E, Johnson RS, Friedlander M. Astrocyte pVHL and HIF-alpha isoforms are required for embryonic-to-adult vascular transition in the eye. J Cell Biol. 2011;195(4):689-701.
34. Izumi-Nagai K, et al. Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol. 2007;170(6):2149-2158. (Pubitemid 47339286)